



Info: info@igbamedicines.org

Medicines UK joins IGBA

Geneva, 17 August 2026

For immediate release

IGBA, the [International Generic and Biosimilar medicines Association](https://www.igbamedicines.org), representing global manufacturers of generic and biosimilar medicines, announced today that Medicines UK has joined IGBA as a new Associate Member.

[Medicines UK](https://www.medicinesuk.org) is the trade body representing the manufacturers and suppliers of nine out of ten of the prescription medicines used by the United Kingdom's National Health Service (NHS).

"It is a pleasure to welcome Medicines UK as a new member," said Jim Keon, IGBA Chair. "Medicines UK is a strong voice for the off-patent medicines industry, helping to build understanding of the role generics and biosimilars play in patient access and healthcare system sustainability. These are goals we share at IGBA, and we look forward to joining forces with Medicines UK in our shared mission of expanding patient access."

Mark Samuels, chief executive of Medicines UK, commented: "We are pleased to be joining IGBA and look forward to contributing actively to strengthened global partnerships on the critical issues affecting the manufacture and supply of off-patent medicines."

"At a time of heightened global pressures, it is essential for our industry to speak with a unified voice on the challenges facing manufacturers worldwide. IGBA provides an important forum for collaboration, engagement and advocacy, and we look forward to supporting its programme of work."

Ana Gaunt, Secretary General of IGBA, added: "We are delighted to welcome Medicines UK to the IGBA community. Medicines UK will strengthen IGBA's work to advance regulatory harmonization and convergence, balanced IP systems, resilient supply chains and sustainable markets worldwide, ultimately benefiting patients and healthcare systems everywhere."

About us: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients' access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.